IQWiG finds no added benefit for Dendreon's Provenge or Gilead's Zydelig
This article was originally published in Scrip
There is no proven benefit for either Dendreon's prostate cancer treatment Provenge (Sipuleucel-T) or Gilead's Zydelig (idelalisib) for follicular lymphoma or chronic lymphocytic leukaemia, according to IQWiG, Germany's health technology appraisal body.
You may also be interested in...
The UK has formally withdrawn its ratification of the Unified Patent Court Agreement, adding to the uncertainty over its future.
Brazil’s medicines regulator has published advice for developers on how to proceed with ongoing clinical trials and bioequivalence studies during the current COVID-19 pandemic.
Obscure drug pricing in Europe could help minimize an “access threat” posed by US pricing policies.